display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR-positive - 1st line (L1)
abemaciclib based treatment
abemaciclib plus aromatase inhibitor MONARCH 3
abemaciclib plus endocrine therapy MonarchE

Study type: